Valuation: Alvotech

Market Cap 1.45B 1.25B 1.17B 1.07B 2.01B 138B 2.04B 13.76B 5.39B 69.33B 5.43B 5.32B 231B P/E 2026 *
15.3x
P/E 2027 * 8.85x
Enterprise Value 2.53B 2.19B 2.05B 1.87B 3.51B 242B 3.56B 24.06B 9.42B 121B 9.5B 9.3B 403B EV / Sales 2026 *
3.86x
EV / Sales 2027 * 3.21x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.86%
1 week+6.43%
Current month-1.58%
1 month+20.33%
3 months+22.51%
6 months-12.61%
Current year-20.96%
1 week 3.75
Extreme 3.75
4.18
1 month 3.04
Extreme 3.04
4.18
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
26/02/26
Aztiq Pharma Partners SARL
BuyCompany 2,701,617 0.9038%
26/02/26 Buy

Founder

2,701,617 0.9038%
15/02/26 Sell

Founder

2,701,617 0.9038%
Change 5-day change 1-year change 3-year change Capi.($)
-0.86%+6.43%-49.47%-54.62% 1.45B
+0.68%-1.01%+2.16%+18.05% 48.42B
+4.07%+3.34%+483.70%+609.03% 43.66B
+4.33%+4.09%+12.80%+88.48% 39.51B
+1.94%+1.06%+26.24%+12.10% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.44%-3.14% - - 16.32B
+3.22%+1.09%+30.42%+133.64% 16.15B
-0.62%+0.29%+3.46%+25.58% 14.16B
+2.35%+7.16%+82.95%+41.92% 13.37B
Average +1.42%+0.44%+68.10%+103.60% 26.46B
Weighted average by Cap. +1.92%-0.58%+100.70%+146.34%

Financials

2026 *2027 *
Net sales 656M 566M 532M 484M 910M 62.69B 923M 6.24B 2.44B 31.42B 2.46B 2.41B 105B 779M 673M 632M 575M 1.08B 74.47B 1.1B 7.41B 2.9B 37.32B 2.92B 2.86B 124B
Net income 91.8M 79.27M 74.43M 67.77M 127M 8.77B 129M 873M 342M 4.4B 345M 337M 14.63B 151M 131M 123M 112M 210M 14.47B 213M 1.44B 563M 7.25B 568M 556M 24.13B
Net Debt 1.08B 936M 879M 800M 1.5B 104B 1.52B 10.3B 4.03B 51.9B 4.07B 3.98B 173B 1.06B 912M 856M 780M 1.46B 101B 1.49B 10.04B 3.93B 50.59B 3.96B 3.88B 168B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
17/08/26 US$3.880 -4.32% 591,495
14/08/26 US$4.055 -0.86% 607,269
13/08/26 US$4.090 +2.00% 559,858
12/08/26 US$4.010 +5.53% 921,390
11/08/26 US$3.800 +0.80% 772,808
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.055USD
Average target price
5.750USD
Spread / Average Target
+41.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock